πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

Showing page 134 of 857 Β· Phase 3 first, then by program name

  1. Pegylated Interferon Alfa 2a

    Vertex Pharmaceuticals (Australia) Pty.

    Infection

    phase 3 small molecule terminated

    1 trial

  2. Pegylated Interferon Alfa-2a

    Hoffmann-La Roche

    Chronic Myelogenous Leukemia

    phase 3 small molecule completed

    1 trial

  3. Pelacarsen

    Novartis Pharmaceuticals

    Atherosclerotic Cardiovascular Disease (ASCVD)

    phase 3 small molecule active

    1 trial

  4. Pemazyre 9 mg tablets, Pemazyre 13.5 mg tablets, Pemazyre 4.5 mg tablets, Gemcitabine 1000 mg, powder for solution for infusion, Cisplatin Ebewe 1 mg/ml – Konzentrat zur Herstellung einer InfusionslΓΆsung

    Incyte

    Cholangiocarcinoma

    phase 3 small molecule active

    1 trial

  5. Pembrolizumab

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 3 mab active

    1 trial

  6. Pembrolizumab

    Incyte

    Renal Cell Carcinoma (RCC)

    phase 3 small molecule completed

    1 trial

  7. Pembrolizumab

    Eisai Co.,

    Endometrial Neoplasms

    phase 3 small molecule completed

    1 trial

  8. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Metastatic Esophageal Squamous Cell Carcinoma

    phase 3 mab active

    1 trial

  9. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Triple Negative Breast Neoplasms

    phase 3 mab completed

    1 trial

  10. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Solid Tumors

    phase 3 small molecule active

    1 trial

  11. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Ovarian Cancer

    phase 3 mab completed

    1 trial

  12. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Urinary Bladder Neoplasms

    phase 3 small molecule active

    1 trial

  13. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Carcinoma, Renal Cell

    phase 3 mab active

    1 trial

  14. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Gastric Neoplasms

    phase 3 mab completed

    1 trial

  15. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Renal Cell Carcinoma

    phase 3 mab completed

    1 trial

  16. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Endometrial Neoplasms

    phase 3 mab active

    1 trial

  17. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Cervical Cancer

    phase 3 mab completed

    1 trial

  18. Pembrolizumab (K)

    Merck KGaA, Darmstadt, Germany

    Breast Cancer

    phase 3 mab active

    1 trial

  19. Pembrolizumab 25 MG/ML [Keytruda]

    United Therapeutics Europe Ltd

    Lung Cancer, Nonsmall Cell

    phase 3 small molecule active

    1 trial

  20. Pembrolizumab/Vibostolimab

    Merck KGaA, Darmstadt, Germany

    Lung Neoplasms

    phase 3 mab completed

    1 trial

  21. Pemetrexed

    Boehringer Ingelheim

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule completed

    1 trial

  22. Pemetrexed

    Regeneron UK Limited

    Carcinoma，Non-Small-Cell Lung

    phase 3 small molecule completed

    1 trial

  23. Pemetrexed

    Eli Lilly and Company

    Non-Small Cell Lung Cancer

    phase 3 small molecule completed

    2 trials

  24. Pemetrexed 500mg/m2 iv

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    NSCLC

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources